Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Total Articles

3
(from Reference Citation Analysis)

Article PDFs (0)

Cited by > 0 (2)

Searched Name

R.F. Manges

Ranked By

Results Analysis

Results Analysis

Indexed Articles

Year Published

Show more Refine

Article Statistics

Refine

Publication Titles

Show more Refine

Grant Agencies

Show more Refine

Category

Show more Refine

Number	Citation Analysis
1	SAFETY AND EFFICACY OF THE PD-L1 INHIBITOR DURVALUMAB WITH R-CHOP OR R² -CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH-RISK DLBCL. Hematol Oncol 2019. [DOI: 10.1002/hon.93_2629] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
2	Results from a Phase 2 Study of Ruxolitinib or Placebo with Capecitabine as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer: The Recap Trial. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu193.26] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
3	APRICoT-P: A phase II randomized placebo controlled study of apricoxib, a potent COX-2 inhibitor in combination with erlotinib and gemcitabine in pancreatic cancer patients. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.tps224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse